Surveillance for Adverse Events After COVID-19 mRNA Vaccination-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Published:2021-10-12 Issue:14 Volume:326 Page:1390
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Klein Nicola P.¹,Lewis Ned¹,Goddard Kristin¹,Fireman Bruce¹,Zerbo Ousseny¹,Hanson Kayla E.²,Donahue James G.²,Kharbanda Elyse O.³,Naleway Allison⁴,Nelson Jennifer Clark⁵,Xu Stan⁶,Yih W. Katherine⁷,Glanz Jason M.⁸⁹,Williams Joshua T. B.¹⁰¹¹,Hambidge Simon J.¹⁰¹¹,Lewin Bruno J.⁶,Shimabukuro Tom T.¹²,DeStefano Frank¹²,Weintraub Eric S.¹²

Affiliation:

1. Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland

2. Marshfield Clinic Research Institute, Marshfield, Wisconsin

3. HealthPartners Institute, Minneapolis, Minnesota

4. Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon

5. Biostatistics Unit, Kaiser Permanente Washington Health Research Institute, Seattle, Washington

6. Research and Evaluation, Kaiser Permanente Southern California, Pasadena

7. Harvard Pilgrim Health Care Institute, Boston, Massachusetts

8. Institute for Health Research, Kaiser Permanente Colorado, Denver

9. Department of Epidemiology, Colorado School of Public Health, Aurora

10. Ambulatory Care Services, Denver Health, Denver, Colorado

11. University of Colorado School of Medicine, Aurora

12. Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2784015/jama_klein_2021_oi_210099_1633976015.05985.pdf

Reference32 articles.

1. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020.;Oliver;MMWR Morb Mortal Wkly Rep,2020

2. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine—United States, December 2020.;Oliver;MMWR Morb Mortal Wkly Rep,2021

3. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.;Polack;N Engl J Med,2020

4. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.;Baden;N Engl J Med,2021

5. The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 vaccine—United States, December 2020.;Dooling;MMWR Morb Mortal Wkly Rep,2021

Cited by 477 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular disease and covid-19: A systematic review;IJC Heart & Vasculature;2024-10

2. Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center;Vaccine;2024-10

3. Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study;Vaccine;2024-10

4. A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines;Expert Review of Vaccines;2024-09-13

5. The descriptive epidemiology of adverse events following two doses of mRNA COVID-19 vaccination in Curaçao, the Caribbean;Infectious Diseases;2024-09-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3